News

The availability of biosimilars -- ‘copies’ of biologics -- is very recent and limited so far to only a few products. Projecting the impact on markets of the appearance of ‘biosimilars’ is still difficult, both for individual products and for the market as a whole. This the first in a series of blog posts about the issues, as discussed at an OHE-sponsored seminar.

HTAinSite is a unique resource that enables subscribers to quickly find relevant information on NICE technology appraisal (TA) decisions and the evidence used to support them. Launched in May 2009, the project is a collaboration involving the OHE, City University London and Abacus International.

Tensions between broad access to new medical technologies and efforts to contain health care costs are perennial. In recent years, this has become evident in the uncomfortable discontinuities that can occur between health technology assessment (HTA) and regulatory approval of medicines. In autumn 2009, OHE and the Institute for Regulatory Science at CMR International collaborated on a two-day workshop on the issues raised.

On 29 June, OHE will collaborate with the Pope Woodhead consultancy to present a workshop on implementing risk sharing and patient access schemes within a market access strategy. Delivered in a highly interactive format, the day will include ample opportunity for lively discussion, group break-outs, role playing scenarios and the sharing of experiences.

Pages